An open-label, long term (52 week) extension study to evaluate the safety, tolerability, and efficacy of treatment with LCZ696 monotherapy and LCZ696 in combination with amlodipine in patients with essential hypertension [EXTENSION OF 700233823]

Trial Profile

An open-label, long term (52 week) extension study to evaluate the safety, tolerability, and efficacy of treatment with LCZ696 monotherapy and LCZ696 in combination with amlodipine in patients with essential hypertension [EXTENSION OF 700233823]

Discontinued
Phase of Trial: Phase III

Latest Information Update: 18 Mar 2017

At a glance

  • Drugs Sacubitril/valsartan (Primary) ; Amlodipine
  • Indications Essential hypertension
  • Focus Adverse reactions
  • Sponsors Novartis
  • Most Recent Events

    • 26 Aug 2014 Status changed from recruiting to discontinued as reported by European Clinical Trials Database record.
    • 10 Apr 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top